Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 6, Issue -, Pages -Publisher
BMC
DOI: 10.1186/1756-8722-6-55
Keywords
Lenalidomide; Immunomodulatory; B-cell; Lymphoma
Categories
Ask authors/readers for more resources
Lenalidomide is an immunomodulatory agent which has been approved for multiple myeloma. Lenalidomide is also effective in and tolerated well by patients with follicular lymphoma, diffuse large B-cell lymphoma, and transformed large cell lymphoma. This review summarizes the results of current preclinical and clinical studies of lenalidomide, alone or in combination with the monoclonal antibody rituximab, as a therapeutic option for these three lymphoma types. This review will serve as a tool guiding future clinical investigations to improve survival rates for these three lymphomas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available